A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors

Status:
NOT_YET_RECRUITING

Trial end date:
2026-12-15

Target enrollment:

Participant gender:

This study is designed to evaluate the safety and efficacy of QLF31907 combination therapy in advanced malignant tumors.

PHASE1

Qilu Pharmaceutical Co., Ltd.

Docetaxel
Irinotecan